United States In Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2012

Product Code GMD15395
Publication Date September 2008
Publisher Global Markets Direct
Product Type Report
Pages 164
ISBN Number not applicable
Change currency
PDF £1,895.00 €2,282 $2,996 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

United States In Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2012

This report is an essential source for in-depth information and data relating to the United States In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the In vitro diagnostic dvices in United States.

Scope

  • The report provides in vitro diagnostics information broken down into detailed categories and segments in United States.
  • Total revenues, end users
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the in vitro diagnostics devices market in United States.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets Covered in the Report
    • 3.1 In Vitro Diagnostics Devices
    • 3.2 Clinical Chemistry Test Reagents
      • 3.2.1 Laboratory Reagents
      • 3.2.2 Clinical Chemistry Calibrators and Controls
      • 3.2.3 Clinical Chemistry Rapid Tests
    • 3.3 Immunochemistry Test Reagents
      • 3.3.1 Disease Specific Markers
      • 3.3.2 Disease Specific Test Reagents
      • 3.3.3 Drug Related Testing Reagents
      • 3.3.4 Hormone Related Testing Reagents
      • 3.3.5 Immunochemistry Calibrators and Controls
      • 3.3.6 Immunochemistry Rapid Tests
    • 3.4 Blood Test Reagents
      • 3.4.1 Hematology Test Reagents
      • 3.4.2 Hemostasis Test Reagents
      • 3.4.3 Tissue Typing Reagents
      • 3.4.4 Monoclonal Antibodies
      • 3.4.5 Cytokines and Immunomodulators
      • 3.4.6 Histology and Cytology Reagents
    • 3.5 Microbiology Test Reagents
      • 3.5.1 Bacteriology Test Reagents
      • 3.5.2 Microbiology Calibrators and Controls
      • 3.5.3 Microbiology Rapid Tests
    • 3.6 Infectious Immunology Test Reagents
      • 3.6.1 Bacteriology
      • 3.6.2 Virology
      • 3.6.3 Parasitology
      • 3.6.4 Infectious Immunology Calibrators and Controls
      • 3.6.5 Infectious Immunology Rapid Tests
    • 3.7 Genetic Test Reagents
    • 3.8 Self Testing
    • 3.9 Instruments
  • 4 Healthcare Sector Review
    • 4.1 Healthcare Expenditure
    • 4.2 Healthcare Infrastructure
      • 4.2.1 Healthcare Personnel Data
      • 4.2.2 Healthcare Facilities Data
    • 4.3 United States Healthcare Trade Statistics
  • 5 Regulation System
    • 5.1 Regulation System
    • 5.2 Medical Equipment Approval Process
      • 5.2.1 Pre-market Approval Process
      • 5.2.2 Intended use and Indications for use
      • 5.2.3 Predicate Device
      • 5.2.4 Safe and Effective
      • 5.2.5 Other Category Devices
      • 5.2.6 Post-Market Approval Process
      • 5.2.7 Compliance and Enforcement
      • 5.2.8 Registration Fee
      • 5.2.9 Approval Time
  • 6 Pricing and Reimbursement
    • 6.1 Government Policies
    • 6.2 Private Insurance
    • 6.3 Diagnosis Related Groups (DRG)
  • 7 Distribution Structure
    • 7.1 Distribution Structure
  • 8 United States Medical Equipment Cross Market Comparison
  • 9 In Vitro Diagnostics In United States
    • 9.1 In Vitro Diagnostics Cross Country Comparison (2000-2012)
    • 9.2 In Vitro Diagnostics, United States, Overall Revenues, 2000-2012
    • 9.3 In Vitro Diagnostics, United States, Company Share (2006-2007)
  • 10 Blood Test Reagents In United States
    • 10.1 Blood Test Reagents Overall Revenue (2000-2012)
      • 10.1.1 Haematology Test Reagents Revenue (2000-2012)
      • 10.1.2 Hemostasis Test Reagents Revenue (2000-2012)
    • 10.2 Blood Test Reagents Distribution Share (2006-2007)
    • 10.3 Blood Test Reagents, United States, Company Share (2006-2007)
  • 11 Clinical Chemistry Test Reagents In United States
    • 11.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2012)
    • 11.2 Clinical Chemistry Test Reagents Distribution Share (2006-2007)
    • 11.3 Clinical Chemistry Test Reagents, United States, Company Share (2006-2007)
  • 12 Genetic Test Reagents In United States
    • 12.1 Genetic Test Reagents Overall Revenue (2000-2012)
    • 12.2 Genetic Test Reagents Distribution Share (2006-2007)
    • 12.3 Genetic Test Reagents, United States, Company Share (2006-2007)
  • 13 Immunochemistry Test Reagents In United States
    • 13.1 Immunochemistry Test Reagents Overall Revenue (2000-2012)
      • 13.1.1 Disease Specific Markers Revenue (2000-2012)
      • 13.1.2 Disease Specific Test Reagents Revenue (2000-2012)
      • 13.1.3 Drug Related Testing Reagents Revenue (2000-2012)
      • 13.1.4 Hormone Related Testing Reagents Revenue (2000-2012)
    • 13.2 Immunochemistry Test Reagents Distribution Share (2006-2007)
    • 13.3 Immunochemistry Test Reagents, United States, Company Share (2006-2007)
  • 14 Infectious Immunology Test Reagents In United States
    • 14.1 Infectious Immunology Test Reagents Overall Revenue (2000-2012)
      • 14.1.1 Virology Revenue (2000-2012)
    • 14.2 Infectious Immunology Test Reagents Distribution Share (2006-2007)
    • 14.3 Infectious Immunology Test Reagents, United States, Company Share (2006-2007)
  • 15 Instruments In United States
    • 15.1 Instruments Overall Revenue (2000-2012)
    • 15.2 Instruments Distribution Share (2006-2007)
    • 15.3 Instruments, United States, Company Share (2006-2007)
  • 16 Microbiology Test Reagents In United States
    • 16.1 Microbiology Test Reagents Overall Revenue (2000-2012)
      • 16.1.1 Bacteriology Test Reagents Revenue (2000-2012)
    • 16.2 Microbiology Test Reagents Distribution Share (2006-2007)
    • 16.3 Microbiology Test Reagents, United States, Company Share (2006-2007)
  • 17 Self Testing In United States
    • 17.1 Self Testing Overall Revenue (2000-2012)
    • 17.2 Self Testing Distribution Share (2006-2007)
    • 17.3 Self Testing, United States, Company Share (2006-2007)
  • 18 F. Hoffmann-La Roche Ltd. Company Profile
    • 18.1 Company Overview
    • 18.2 Value Chain Analysis
      • 18.2.1 Manufacturing
      • 18.2.2 Product Development
      • 18.2.3 Sales and Marketing
  • 19 Beckman Coulter, Inc. Company Profile
    • 19.1 Company Overview
    • 19.2 Value Chain Analysis
      • 19.2.1 Manufacturing
      • 19.2.2 Product Development
      • 19.2.3 Sales and Marketing
    • 19.3 Beckman Coulter, Inc. Pipeline Products
      • 19.3.1 Beckman Coulter, Inc. Pipeline Products by Equipment Type
      • 19.3.2 Beckman Coulter, Inc. Pipeline Products by Development Stage
      • 19.3.3 Beckman Coulter, Inc. Pipeline Products by Therapy Area
      • 19.3.4 Beckman Coulter, Inc. Pipeline Products by News Summary
  • 20 Dade Behring Holdings, Inc. Company Profile
    • 20.1 Company Overview
    • 20.2 Dade Behring Holdings, Inc. Pipeline Products
      • 20.2.1 Dade Behring Holdings, Inc. Pipeline Products by Equipment Type
      • 20.2.2 Dade Behring Holdings, Inc. Pipeline Products by Development Stage
      • 20.2.3 Dade Behring Holdings, Inc. Pipeline Products by Therapy Area
      • 20.2.4 Dade Behring Holdings, Inc. Pipeline Products by News Summary
  • 21 Abbott Laboratories Company Profile
    • 21.1 Company Overview
    • 21.2 Value Chain Analysis
      • 21.2.1 Manufacturing
      • 21.2.2 Product Development
      • 21.2.3 Sales and Marketing
    • 21.3 Abbott Laboratories Pipeline Products
      • 21.3.1 Abbott Laboratories Pipeline Products by Equipment Type
      • 21.3.2 Abbott Laboratories Pipeline Products by Development Stage
      • 21.3.3 Abbott Laboratories Pipeline Products by Therapy Area
      • 21.3.4 Abbott Laboratories Pipeline Products by Clinical Trials
      • 21.3.5 Abbott Laboratories Pipeline Products by News Summary
  • 22 Siemens Medical Solutions Company Profile
    • 22.1 Company Overview
    • 22.2 Value Chain Analysis
      • 22.2.1 Manufacturing
      • 22.2.2 Product Development
      • 22.2.3 Sales and Marketing
    • 22.3 Siemens Medical Solutions Pipeline Products
      • 22.3.1 Siemens Medical Solutions Pipeline Products by Equipment Type
      • 22.3.2 Siemens Medical Solutions Pipeline Products by Development Stage
      • 22.3.3 Siemens Medical Solutions Pipeline Products by Therapy Area
      • 22.3.4 Siemens Medical Solutions Pipeline Products by News Summary
  • 23 Gen-Probe Incorporated Company Profile
    • 23.1 Company Overview
    • 23.2 Value Chain Analysis
      • 23.2.1 Manufacturing
      • 23.2.2 Product Development
      • 23.2.3 Sales and Marketing
    • 23.3 Gen-Probe Incorporated Pipeline Products
      • 23.3.1 Gen-Probe Incorporated Pipeline Products by Equipment Type
      • 23.3.2 Gen-Probe Incorporated Pipeline Products by Development Stage
      • 23.3.3 Gen-Probe Incorporated Pipeline Products by Therapy Area
      • 23.3.4 Gen-Probe Incorporated Pipeline Products by Clinical Trials
      • 23.3.5 Gen-Probe Incorporated Pipeline Products by News Summary
  • 24 A&G Pharmaceutical, Inc. Company Profile
    • 24.1 Company Overview
    • 24.2 A&G Pharmaceutical, Inc. Pipeline Products
      • 24.2.1 A&G Pharmaceutical, Inc. Pipeline Products by Equipment Type
      • 24.2.2 A&G Pharmaceutical, Inc. Pipeline Products by Development Stage
      • 24.2.3 A&G Pharmaceutical, Inc. Pipeline Products by Therapy Area
      • 24.2.4 A&G Pharmaceutical, Inc. Pipeline Products by News Summary
  • 25 Applied NeuroSolutions, Inc. Company Profile
    • 25.1 Company Overview
  • 26 Baxter International Inc. Company Profile
    • 26.1 Company Overview
    • 26.2 Value Chain Analysis
      • 26.2.1 Manufacturing
      • 26.2.2 Product Development
      • 26.2.3 Sales and Marketing
  • 27 Biovest International, Inc. Company Profile
    • 27.1 Company Overview
  • 28 BioVision, Inc. Company Profile
    • 28.1 Company Overview
  • 29 Egenix, Inc. Company Profile
    • 29.1 Company Overview
  • 30 Express Biotech International Company Profile
    • 30.1 Company Overview
  • 31 Genomic Health, Inc. Company Profile
    • 31.1 Company Overview
  • 32 Genzyme Corporation Company Profile
    • 32.1 Company Overview
  • 33 Haemonetics Corporation Company Profile
    • 33.1 Company Overview
    • 33.2 Value Chain Analysis
      • 33.2.1 Manufacturing
      • 33.2.2 Product Development
      • 33.2.3 Sales and Marketing
  • 34 ImmTech, Inc Company Profile
    • 34.1 Company Overview
  • 35 ImmunoVision, Inc. Company Profile
    • 35.1 Company Overview
  • 36 Financial Deals Landscape
    • 36.1 Acquisition
      • 36.1.1 Paul Kennedy And Patrice Debregeas Acquires 72% Stakes In IVAX Diagnostics From Teva Pharmaceutical Industries
      • 36.1.2 Immucor Acquires BioArray Solutions
      • 36.1.3 The Elitech To Acquire Nanogen
    • 36.2 Venture Financing
      • 36.2.1 Molecular Biometrics Secures $12 Million In Series A Financing
      • 36.2.2 BioImagene Secures $26 Million In Series D Financing
      • 36.2.3 Chronix Biomedical Secures $2.27 Million In Second Round Of Financing
  • 37 Recent Developments
    • 37.1 Product Annoucements
      • 37.1.1 Aug 18, 2008: Biotest Receives FDA Approval To Market Its Full Line of Traditional Blood Bank Reagents
  • 38 APPENDIX
    • 38.1 Global Markets Direct Research Methodology
    • 38.2 Coverage
    • 38.3 Secondary Research
    • 38.4 Primary Research
    • 38.5 Models
    • 38.6 Forecasts
    • 38.7 Expert Panels
    • 38.8 Currency Conversion
    • 38.9 Contact Us
    • 38.10 Disclaimer
  • 1.1 List of Tables
    • Table 1: United States Healthcare Expenditure, 2003-2010
    • Table 2: United States Healthcare Expenditure by Age (per person), 2000-2003
    • Table 3: United States Healthcare Expenditure by Sex (per person), 2000-2003
    • Table 4: United States Healthcare Expenditure by Race (per person), 2000-2003
    • Table 5: United States Personal Healthcare Expenditure by Type, 2000-2004
    • Table 6: United States Personal Healthcare Expenditure by Source, 2000-2004
    • Table 7: Total Number of Doctors in the United States, 2003-2010
    • Table 8: Number of Doctors by Specialty in the United States, 2003-2010
    • Table 9: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004
    • Table 10: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004 (Cont.)
    • Table 11: Total Hospitals in the United States, 2000-2004
    • Table 12: Community Hospitals by Number of Beds in the United States, 2000-2004
    • Table 13: Number of Hospital Beds in the United States, 2000-2004
    • Table 14: Number of Hospital Beds by Range in the United States, 2000-2004
    • Table 15: United States Healthcare Trade Statistics, 2001-2006
    • Table 16: Medical Equipment Registration Fee in United States, 2007
    • Table 17: Medical Device Approval Time in United States, 2004
    • Table 18: United States, Medical Equipment Market Comparison
    • Table 19: In Vitro Diagnostics Cross Country Comparison (2000-2012)
    • Table 20: In Vitro Diagnostics, United States, Overall Revenues ($ mn), 2000-2012
    • Table 21: In Vitro Diagnostics Market, United States, Portfolio Analysis
    • Table 22: In Vitro Diagnostics, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 23: In Vitro Diagnostics, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 24: In Vitro Diagnostics, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 25: Blood Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 26: Blood Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 27: Haematology Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 28: Haematology Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 29: Hemostasis Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 30: Hemostasis Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 31: Blood Test Reagents, United States, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 32: Blood Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 33: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 34: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 35: Clinical Chemistry Test Reagents, United States, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 36: Clinical Chemistry Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 37: Genetic Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 38: Genetic Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 39: Genetic Test Reagents, United States, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 40: Genetic Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 41: Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 42: Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 43: Disease Specific Markers, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 44: Disease Specific Markers, United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 45: Disease Specific Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 46: Disease Specific Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 47: Drug Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 48: Drug Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 49: Hormone Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 50: Hormone Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 51: Immunochemistry Test Reagents, United States, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 52: Immunochemistry Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 53: Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 54: Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 55: Virology, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 56: Virology, United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 57: Infectious Immunology Test Reagents, United States, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 58: Infectious Immunology Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 59: Instruments, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 60: Instruments, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 61: Instruments, United States, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 62: Instruments, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 63: Microbiology Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 64: Microbiology Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 65: Bacteriology Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 66: Bacteriology Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 67: Microbiology Test Reagents, United States, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 68: Microbiology Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 69: Self Testing, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 70: Self Testing, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 71: Self Testing, United States, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 72: Self Testing, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 73: Beckman Coulter, Inc. Pipeline Products by Equipment Type
    • Table 74: Beckman Coulter, Inc. Pipeline Products By Development Stage
    • Table 75: Beckman Coulter, Inc. Pipeline Products By Therapy Area
    • Table 76: Beckman Coulter, Inc. Pipeline Products By News Summaries
    • Table 77: Dade Behring Holdings, Inc. Pipeline Products by Equipment Type
    • Table 78: Dade Behring Holdings, Inc. Pipeline Products By Development Stage
    • Table 79: Dade Behring Holdings, Inc. Pipeline Products By Therapy Area
    • Table 80: Dade Behring Holdings, Inc. Pipeline Products By News Summaries
    • Table 81: Abbott Laboratories Pipeline Products by Equipment Type
    • Table 82: Abbott Laboratories Pipeline Products By Development Stage
    • Table 83: Abbott Laboratories Pipeline Products By Therapy Area
    • Table 84: Abbott Laboratories Pipeline Products By Clinical Trials
    • Table 85: Abbott Laboratories Pipeline Products By News Summaries
    • Table 86: Siemens Medical Solutions Pipeline Products by Equipment Type
    • Table 87: Siemens Medical Solutions Pipeline Products By Development Stage
    • Table 88: Siemens Medical Solutions Pipeline Products By Therapy Area
    • Table 89: Siemens Medical Solutions Pipeline Products By News Summaries
    • Table 90: Gen-Probe Incorporated Pipeline Products by Equipment Type
    • Table 91: Gen-Probe Incorporated Pipeline Products By Development Stage
    • Table 92: Gen-Probe Incorporated Pipeline Products By Therapy Area
    • Table 93: Gen-Probe Incorporated Pipeline Products By Clinical Trials
    • Table 94: Gen-Probe Incorporated Pipeline Products By News Summaries
    • Table 95: A&G Pharmaceutical, Inc. Pipeline Products by Equipment Type
    • Table 96: A&G Pharmaceutical, Inc. Pipeline Products By Development Stage
    • Table 97: A&G Pharmaceutical, Inc. Pipeline Products By Therapy Area
    • Table 98: A&G Pharmaceutical, Inc. Pipeline Products By News Summaries
    • Table 99: Currency Conversion from USD to Local Currency at 2007 Constant Rate
  • 1.2 List of Figures
    • Figure 1: United States, Healthcare Expenditure by Source, 2003
    • Figure 2: United States, Healthcare Infrastructure, Top Level View, 2007
    • Figure 3: Healthcare Expenses Segmentation by End User, 2003
    • Figure 4: Medical Equipment Approval Process in the United States, 2007
    • Figure 5: PMA Approval Process in the United States, 2007
    • Figure 6: The 510(k) Approval Process for Medical Devices in the United States, 2007
    • Figure 7: Reimbursement Structure in the United States, 2007
    • Figure 8: Distribution Structure of Medical Equipment in the United States, 2006
    • Figure 9: United States, Medical Equipment Market Comparison,2007
    • Figure 10: In Vitro Diagnostics Cross Country Comparison (2000-2012)
    • Figure 11: In Vitro Diagnostics, United States, Overall Revenues ($ mn), 2000-2012
    • Figure 12: In Vitro Diagnostics Market, United States, Portfolio Analysis
    • Figure 13: In Vitro Diagnostics, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 14: In Vitro Diagnostics, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 15: In Vitro Diagnostics, United States, Company Share (%), 2007
    • Figure 16: Blood Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 17: Blood Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 18: Haematology Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 19: Haematology Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 20: Hemostasis Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 21: Hemostasis Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 22: Blood Test Reagents, United States, Company Share (%), 2007
    • Figure 23: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 24: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 25: Clinical Chemistry Test Reagents, United States, Company Share (%), 2007
    • Figure 26: Genetic Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 27: Genetic Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 28: Genetic Test Reagents, United States, Company Share (%), 2007
    • Figure 29: Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 30: Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 31: Disease Specific Markers, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 32: Disease Specific Markers, United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 33: Disease Specific Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 34: Disease Specific Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 35: Drug Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 36: Drug Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 37: Hormone Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 38: Hormone Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 39: Immunochemistry Test Reagents, United States, Company Share (%), 2007
    • Figure 40: Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 41: Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 42: Virology, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 43: Virology, United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 44: Infectious Immunology Test Reagents, United States, Company Share (%), 2007
    • Figure 45: Instruments, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 46: Instruments, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 47: Instruments, United States, Company Share (%), 2007
    • Figure 48: Bacteriology Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 49: Bacteriology Test Reagents, United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 50: Microbiology Test Reagents, United States, Company Share (%), 2007
    • Figure 51: Self Testing, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 52: Self Testing, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 53: Self Testing, United States, Company Share (%), 2007
    • Figure 54: F. Hoffmann-La Roche Ltd Value Chain Analysis
    • Figure 55: Beckman Coulter, Inc. Value Chain Analysis
    • Figure 56: Abbott Laboratories Value Chain Analysis
    • Figure 57: Siemens Medical Solutions Value Chain Analysis
    • Figure 58: Gen-Probe Incorporated Value Chain Analysis
    • Figure 59: Baxter International Inc. Value Chain Analysis
    • Figure 60: Haemonetics Corporation Value Chain Analysis
    • Figure 61: Global Markets Direct Methodology